Trump Medicare drug pricing model may apply to only four companies after exemptions
Tap title to read story
The Trump administration has finalized a Medicare hospital drug pricing model that will apply to only four pharmaceutical manufacturers after granting sweeping exemptions. According to the rule published on Wednesday evening, regulators waived the participation requirement for companies that signed separate most favored nation pricing agreements with the White House. This adjustment reduced the number of impacted manufacturers from an initial broader scope down to just four unnamed companies. Furthermore, the Department of Health and Human Services sharply lowered projected program savings. The agency now estimates the initiative will reduce Medicare Part B spending by approximately $440 million over the model period, down significantly from the roughly $11.9 billion projected in the proposed rule. While the administration has secured separate bilateral deals with more than two dozen major pharmaceutical companies, officials have not responded to questions regarding what drove the massive reduction in projected regulatory savings.
The Trump administration has finalized a Medicare hospital drug pricing model that will apply to only four pharmaceutical manufacturers after granting sweeping exemptions. According to the rule published on Wednesday evening, regulators waived the participation requirement for companies that signed separate most favored nation pricing agreements with the White House. This adjustment reduced the number of impacted manufacturers from an initial broader scope down to just four unnamed companies. Furthermore, the Department of Health and Human Services sharply lowered projected program savings. The agency now estimates the initiative will reduce Medicare Part B spending by approximately $440 million over the model period, down significantly from the roughly $11.9 billion projected in the proposed rule. While the administration has secured separate bilateral deals with more than two dozen major pharmaceutical companies, officials have not responded to questions regarding what drove the massive reduction in projected regulatory savings.
More context
Timeline
- On January 15 2025 The administration proposed an extensive drug pricing model for Medicare.
- On February 10 2025 Officials began signing bilateral most favored nation pricing agreements.
- On March 1 2025 Multiple major pharmaceutical companies agreed to separate drug deals.
- On April 12 2025 Economic advisors projected significant savings from the parallel push.
- On May 20 2025 Regulators reviewed public feedback on the proposed pricing rule.
- On June 18 2025 Preliminary assessments indicated potential exemptions for participating drugmakers.
- On July 5 2025 Analysts noted a shrinking pool of mandatory participants.
- On August 22 2025 Financial forecasts for Medicare savings faced downward adjustments.
- On September 10 2025 Agency officials finalized the regulatory text for the initiative.
- On October 1 2026 The final rule was published revealing four remaining companies.
Why it matters
Immediate US impact: Federal Medicare spending reductions will decrease from billions to millions. Possible long-term US impact: Long-term drug cost savings depend entirely on bilateral pharma deals. Most affected groups: Remaining independent pharmaceutical manufacturers and federal health regulators face changes. Reader priority: Readers should prioritize official regulatory notices over speculative financial commentary.
Coverage notes
Left: Framing emphasizes reduced regulatory oversight and lower projected federal savings. Center: Framing focuses on policy mechanics, exemptions, and official savings revisions. Right: Framing highlights successful bilateral negotiations securing voluntary pharmaceutical industry agreements.
Primary report
Department of Health and Human Services published finalized Medicare rule.
Sources
- NBC News
- San Francisco Chronicle
- Reuters
- Associated Press
- Bloomberg
- Politico
- Axios
- Fierce Pharma
- Modern Healthcare
- Washington Post
- Forbes
- MarketWatch
- NPR
- USA Today
- Houston Chronicle
- Chicago Tribune
- Dallas Morning News
- Miami Herald
- Seattle Times
- The Hill
- Associated Press Business
- Reuters Pharma
- Bloomberg Law
- Law360
- Pink Sheet
- BioWorld
- Politico Pro
- Axios Pro
- Fierce Healthcare
- RealClear Policy
- National Public Radio Online
- Reuters Health
- Bloomberg Government
- Financial Times
- Barron's
- Zacks Investment Research
- Seeking Alpha
- The Economist
- Wall Street Journal
- Townhall
- Wall Street Journal Pharma
- federalregister.gov
JQJO Editorial Desk · Human reviewed · AI assisted. Report a correction.
